{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:48:41Z","timestamp":1792241321561,"version":"4.4.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI19C0481, HC19C0147"],"award-info":[{"award-number":["HI19C0481, HC19C0147"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We compared the impact of tamoxifen alone or with ovarian function suppression (OFS) on bone mineral density (BMD) in premenopausal patients after chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Of 1483 premenopausal women enrolled in the ASTRRA study, we included 522 who underwent BMD examinations at diagnosis and 3 and 5 years after diagnosis. All BMD measurements were performed using the same scanner in each center across different time points. Patients were stratified into three groups: within the expected range for age (A, Z-score&amp;gt;-1.0), below the expected range (B,-2.0\u2264 Z-score \u2264-1.0), and low bone mineral density for chronological age (C, Z-score&amp;lt; -2.0) groups. We examined changes in groups from baseline to &amp;gt;3-year and 5-year periods to identify any deterioration in BMD. We conducted a subset analysis using the Asan Medical Center (AMC; n=141) data, focusing on the absolute value of bone density (in g\/cm\n                      <jats:sup>2<\/jats:sup>\n                      unit).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 522 included patients (median age, 41.1 years) had a higher bone loss incidence in the OFS addition group at baseline (p=0.028). The tamoxifen-only and tamoxifen+OFS groups did not differ significantly in terms of changes in BMD categories from baseline to 3 (p=0.567) or 5 years (p=0.600). The OFS addition group had a significantly increased risk of BMD deterioration when randomized at the first visit (odds ratio=2.970, p=0.008). Within the AMC subset, the OFS addition group exhibited significantly decreased BMD in the spine (p=0.023) and femur (p=0.040) from the baseline to 3-year period. A non-significantly decreased BMD occurred from the baseline to 5 years in the spine and femur.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings highlighted the deleterious impact on BMD following OFS addition, compared with tamoxifen only treatment. Early OFS exerted an even more detrimental influence on bone health in premenopausal patients with estrogen receptor-positive breast cancer and recovered ovarian function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Abbreviations<\/jats:title>\n                    <jats:p>ANOVA, analysis of variance; BMD, one mineral density; CTIBL, Cancer treatment-induced bone loss; DXA, dual-energy X-ray absorptiometry; HER2 human epidermal growth factor receptor 2; L-spin, lumbar spine; OFS, ovarian function suppression; TAM, tamoxifen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1465256","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:20:16Z","timestamp":1759407616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study"],"prefix":"10.3389","volume":"15","author":[{"given":"Eunju","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsik","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Gyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soong June","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hwan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Sung","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jo","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Wan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geum Hee","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanheun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk Jae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Bum","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Kyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr448","article-title":"Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21\/07)","volume":"23","author":"Zaman","year":"2012","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05567-9","article-title":"Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial","volume":"180","author":"van Hellemond","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.017","article-title":"Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report","volume":"151","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.06.024","article-title":"Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure","volume":"103","author":"Ramchand","year":"2017","journal-title":"Bone"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisdottir","year":"2004","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/bonekey.2015.60","article-title":"Cancer Treatment-Induced Bone Loss in women with breast cancer","volume":"4","author":"Hadji","year":"2015","journal-title":"Bonekey Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-013-0181-0","article-title":"Skeletal manifestations of treatment of breast cancer on premenopausal women","volume":"11","author":"Doo","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e567","article-title":"Bone health in adults treated with endocrine therapy for early breast or prostate cancer","author":"Poznak","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011101)92:9<2419::AID-CNCR1591>3.0.CO;2-K","article-title":"High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors","volume":"92","author":"Banfi","year":"2001","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-015-0266-z","article-title":"Chemotherapy- and irradiation-induced bone loss in adults with solid tumors","volume":"13","author":"Wissing","year":"2015","journal-title":"Curr Osteoporos Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-010-0899-7","article-title":"Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency","volume":"123","author":"Cameron","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00052","article-title":"Cancer treatment-induced bone loss\u00a0in women with breast cancer and men with prostate cancer","volume":"2","author":"Taxel","year":"2018","journal-title":"J Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Richard","year":"1992","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13735","article-title":"Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia","volume":"89","author":"Grossmann","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05566-w","article-title":"Changes in bone\u00a0mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients","volume":"180","author":"Kim","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.506","article-title":"Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-023-01414-1","article-title":"Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer","volume":"41","author":"Takahashi","year":"2023","journal-title":"J Bone Mineral Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad247","article-title":"The\u00a0clinical\u00a0benefits of antiresorptive agents in patients with primary breast cancer receiving adjuvant endocrine therapy: A systematic review with pairwise and network meta-analysis","volume":"108","author":"Wang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.6.603","article-title":"Clinical considerations in premenopausal osteoporosis","volume":"164","author":"Gourlay","year":"2004","journal-title":"Arch Internal Med"}],"updated-by":[{"DOI":"10.3389\/fonc.2025.1729229","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1465256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:21:14Z","timestamp":1762510874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1465256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1465256"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1465256","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1465256"}}